Cite
Nivolumab-induced thyroid dysfunction in patients with lung cancer.
MLA
Ramos-Levi, Ana M., et al. “Nivolumab-Induced Thyroid Dysfunction in Patients with Lung Cancer.” Endocrinologia, Diabetes y Nutricion, vol. 66, no. 1, Jan. 2019, pp. 26–34. EBSCOhost, https://doi.org/10.1016/j.endinu.2018.05.005.
APA
Ramos-Levi, A. M., Rogado, J., Sanchez-Torres, J. M., Colomer, R., & Marazuela, M. (2019). Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinologia, Diabetes y Nutricion, 66(1), 26–34. https://doi.org/10.1016/j.endinu.2018.05.005
Chicago
Ramos-Levi, Ana M, Jacobo Rogado, Jose Miguel Sanchez-Torres, Ramón Colomer, and Mónica Marazuela. 2019. “Nivolumab-Induced Thyroid Dysfunction in Patients with Lung Cancer.” Endocrinologia, Diabetes y Nutricion 66 (1): 26–34. doi:10.1016/j.endinu.2018.05.005.